國家衛生研究院 NHRI:Item 3990099045/13837
English  |  正體中文  |  简体中文  |  Items with full text/Total items : 12145/12927 (94%)
Visitors : 857069      Online Users : 158
RC Version 6.0 © Powered By DSPACE, MIT. Enhanced by NTU Library IR team.
Scope Tips:
  • please add "double quotation mark" for query phrases to get precise results
  • please goto advance search for comprehansive author search
    •  Adv. Search
    Home ‧ Login ‧ Upload ‧ Help ‧ About ‧ Administer Goto mobile version


    Please use this identifier to cite or link to this item: http://ir.nhri.org.tw/handle/3990099045/13837


    Title: Network meta-analysis and trial sequential analysis for atrial fibrillation patients receiving PCI or with ACS
    Authors: Yang, SM;Huang, CJ;Chen, CH;Yu, WC;Sung, SH;Guo, CY;Chuang, SY;Cheng, HM;Chiang, CE
    Contributors: Institute of Population Health Sciences
    Abstract: BACKGROUND: In patients with atrial fibrillation (AF) and acute coronary syndrome (ACS) or undergoing percutaneous coronary intervention (PCI), choosing the most appropriate antithrombotic treatment remains a dilemma. We aimed to compare the relative efficacy and safety outcomes of antithrombotic drugs in patients with AF after undergoing PCI or ACS. METHODS: Randomized controlled trials were systematically searched on PubMed, EMBASE, and the Cochrane Library. Five studies (11,532 patients) were included in the network meta-analysis (NMA). Trial sequential analysis (TSA) was performed to assess the reliability and conclusiveness of the meta-analysis comparing the dual antithrombotic therapy strategies with the triple antithrombotic therapy strategy. RESULTS: Compared with vitamin K antagonist (VKA) + dual antiplatelet therapy (DAPT), novel oral anticoagulant (NOAC) + P2Y12 inhibitor was associated with a significantly better trial-defined primary safety outcome (odds ratio: 0.53; 95% CI: 0.31 - 0.90) and the lowest probability of thrombolysis in myocardial infarction (TIMI) major bleeding and intracranial hemorrhage using the cumulative ranking technique. In patients omitting aspirin, TSA demonstrated conclusive evidence with significant decreases in all safety outcomes and inconclusive evidence with a non-significant increase in in-stent thrombosis (risk ratio: 1.32; TSA-adjusted 95% CI: 0.54 - 3.24) and myocardial infarction (risk ratio: 1.19; TSA-adjusted 95% CI: 0.84 - 1.68). CONCLUSION: In patients with AF receiving PCI or with ACS, NOAC + P2Y12 inhibitor was associated with the lowest bleeding risk but resulted in a statistically non-significant, numerically greater risk for stent thrombosis and myocardial infarction, suggesting that triple antithrombotic therapy (TAT) should still be an option for certain patients at a high risk of stent thrombosis or myocardial infarction.
    Date: 2022-01-01
    Relation: Journal of the Chinese Medical Association. 2022 Jan 1;85(1):59-66.
    Link to: http://dx.doi.org/10.1097/jcma.0000000000000651
    JIF/Ranking 2023: http://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&SrcAuth=NHRI&SrcApp=NHRI_IR&KeyISSN=1726-4901&DestApp=IC2JCR
    Cited Times(WOS): https://www.webofscience.com/wos/woscc/full-record/WOS:000838769100009
    Cited Times(Scopus): https://www.scopus.com/inward/record.url?partnerID=HzOxMe3b&scp=85123457260
    Appears in Collections:[Shao-Yuan Chuang] Periodical Articles

    Files in This Item:

    File Description SizeFormat
    PUB34759208.pdf1830KbAdobe PDF188View/Open


    All items in NHRI are protected by copyright, with all rights reserved.

    Related Items in TAIR

    DSpace Software Copyright © 2002-2004  MIT &  Hewlett-Packard  /   Enhanced by   NTU Library IR team Copyright ©   - Feedback